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Background
IgE binding via the high affinity FcεRI receptor modu-
lates FcεRI expression and cytokine production in mast
cells. Antigen crosslinking of bound IgE further activates
mast cells, inducing degranulation and inflammatory
mediator release. Omalizumab (Xolair; Genentech Inc)
is a recombinant human monoclonal anti-IgE antibody
that prevents IgE binding to FcεRI.
Objective
We investigated the effects of omalizumab on IgE-
mediated responses in human mast cells.
Methods
LAD2 and CD34
+-derived human mast cell degranula-
tion was determined by measuring the release of the
granular enzyme, b-hexosaminidase. Toll-like receptor
(TLR) expression was measured by quantitative (qPCR)
and western blot analysis. IgE binding and FcεRI expres-
sion was determined by flow cytometry.
Results
Omalizumab (10 ug/mL) inhibited IgE binding to LAD2
cells by 78% (P=0.007) compared to untreated control.
Omalizumab (10 ug/mL) further blocked IgE-dependent
upregulation of FcεRI expression by 90% (P=0.03). In
addition, omalizumab removed FcεRI-bound IgE in a
time-dependent manner; an effect that was detected as
early as 24 hrs (57% removal; P<0.001) after addition of
omalizumab resulting in a concomitant decrease in IgE-
dependent FcεRI expression (30%; P<0.001). Omalizu-
mab attenuated degranulation induced by anti-IgE cross-
linking of bound IgE in a dose dependent manner, with
66% inhibition (P<0.0001) at 25 ug/ml. Furthermore,
100 ug/ml omaluzimab prevented cysteinyl leukotriene
production and FcεRI–dependent modulation of TLR
expression.
Conclusions
Omalizumab inhibits IgE and IgE/anti-IgE dependent
degranulation and receptor expression by human mast
cells. Furthermore, omalizumab is able to remove pre-
bound IgE from sensitized mast cells thereby reducing
their response to FcεRI-dependent signals. This data
suggests that omalizumab is an effective inhibitor of
both sensitized and unsensitized human mast cells.
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